College of Pharmacy, Center for Cell Signaling and Drug Discovery Research, Ewha Womans University, Seoul, Republic of Korea.
Biomaterials. 2011 Aug;32(22):5262-8. doi: 10.1016/j.biomaterials.2011.03.074. Epub 2011 May 12.
We show here, that the proapoptotic peptide, KLAKLAKKLAKLAK (KLA), which by itself does not penetrate cell membranes, can do so when fused to a protein transduction domain derived from NH(2)-terminus of translationally controlled tumor protein (TCTP-PTD, MIIYRDLISH). Once inside the cell, the conjugated KLA exerts its proapoptotic activity to inhibit tumor growth. We evaluated the cellular uptake of KLA fused to TCTP-PTD (hereafter called TCTP-KLA) and its effect on cancer cell viability. The IC(50) of TCTP-KLA was between 7 and 10 μmol/L. We also evaluated its anti-tumor activity in vivo by injecting it into xenografts of lung carcinoma in Balb/c nude mice. Tumor growth inhibition resulting from treatment with TCTP-KLA was better than that of TAT-KLA. These results suggest that TCTP-KLA can be applied to design cancer therapeutics.
我们在这里展示,本身不能穿透细胞膜的促凋亡肽 KLAKLAKKLAKLAK(KLA),当与源自翻译控制肿瘤蛋白(TCTP-PTD,MIIYRDLISH)氨基末端的蛋白转导结构域融合时,可以穿透细胞膜。一旦进入细胞内,共轭的 KLA 发挥其促凋亡活性以抑制肿瘤生长。我们评估了融合到 TCTP-PTD 的 KLA(以下简称 TCTP-KLA)的细胞摄取及其对癌细胞活力的影响。TCTP-KLA 的 IC(50)值在 7 到 10 μmol/L 之间。我们还通过将其注射到 Balb/c 裸鼠的肺癌异种移植物中,在体内评估了其抗肿瘤活性。TCTP-KLA 治疗导致的肿瘤生长抑制优于 TAT-KLA。这些结果表明,TCTP-KLA 可用于设计癌症治疗药物。